The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Late-Stage Pipeline Conference Call

2 Dec 2015 07:00

RNS Number : 6560H
AstraZeneca PLC
02 December 2015
 

LATE-STAGE PIPELINE CONFERENCE CALL

FOR INVESTORS AND ANALYSTS

 

 

AstraZeneca PLC ("AstraZeneca", "the Company") will today host a conference call for investors and analysts. This will focus on key potential medicines within the late-stage pipeline and will provide further details on the progress made in 2015 and the anticipated news flow in 2016. No material new information will be included; the call is intended to offer additional insight on the pipeline.

 

The event will be led by Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer, alongside AstraZeneca experts from each of the Company's main therapy areas and will take place at 16:00 - 17:30 GMT (11:00 - 12:30 EST).

The dial-in details for the conference call are as follows:

UK

0800 694 2370

US

866 977 7645

International

+44 1452 557749

Sweden

0200 883 079

Code

79258160

 

The accompanying presentation will be available for download at astrazeneca.com/investors one hour prior to the start of the call. A link to the live audio webcast will also be available at this address. An indexed version and transcript of the webcast will be published in due course.

 

A replay of the call can be accessed from 17:30 GMT today via the following numbers:

 

UK

0800 953 1533

US

866 247 4222

International

+44 1452 550000

Code

79258160

 

Reporting Calendar

The Company intends to publish its full-year financial results on 4 February 2016.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology - as well as in infection and neuroscience. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit: www.astrazeneca.com

 

CONTACTS

 

Media Enquiries

 

 

 

Esra Erkal-Paler

 

UK/Global

+44 20 7604 8030

Vanessa Rhodes

 

UK/Global

+44 20 7604 8037

Karen Birmingham

UK/Global

+44 20 7604 8120

Jacob Lund

 

Sweden

+46 8 553 260 20

Michele Meixell

US

+1 302 885 2677

Investor Enquiries

 

UK

 

Thomas Kudsk Larsen

Oncology

+44 7818 524185

 

Eugenia Litz

RIA

+44 7884 735627

 

Nick Stone

CVMD

+44 7717 618834

 

Craig Marks

Finance

+44 7881 615764

 

Christer Gruvris

Consensus Forecasts

+44 7827 836825

 

US

 

Lindsey Trickett

Oncology, ING

+1 240 543 7970

 

Mitchell Chan

Oncology

+1 240 477 3771

 

Toll-Free

+1 866 381 7277

 

 

Key: RIA - Respiratory, Inflammation & Autoimmunity, CVMD - Cardiovascular & Metabolic Disease,

ING - Infection, Neuroscience & Gastrointestinal

 

 

02 December 2015

 

 

-ENDS-

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCTBBJTMBMMTBA

Related Shares

Back to RNS

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.